A nterior cervical discectomy and fusion is a common treatment for radiculopathy and myelopathy. The procedure is well tolerated and, in correctly selected patients, the results are highly successful [1] [2] [3] . Longer follow-up has revealed that up to 25% of patients may develop recurrent radicular symptoms from adjacent segment disc degeneration 4 . Furthermore, reoperations may be required to treat complications of fusion, such as nonunion and bone graft collapse or expulsion. In select patients, cervical arthroplasty is a potential substitute for cervical fusion after anterior neural decompression.
In the United States, a prospective, randomized controlled clinical trial was performed to evaluate the safety and effectiveness of the Bryan Cervical Disc (Medtronic Spinal and Biologics, Memphis, Tennessee) compared with fusion with allograft and plate stabilization. The indications for surgery were radiculopathy or myelopathy in patients with single-level cervical disc disease. The twenty-four-month results of this trial have been published 5 . The overall success and other patient-reported outcome measures indicated that treatment with the Bryan cervical disc arthroplasty achieved significantly superior results and allowed patients to return to work sooner. The current investigation was prompted by the relatively short follow-up period for the implanted motion-bearing device in the prior study. Further, to assess cost-effectiveness, knowledge of the durability of improvement in self-reported outcomes compared with preoperative states is essential. The purpose of this study was to evaluate clinical functional outcomes four years after either Bryan cervical disc arthroplasty or anterior cervical discectomy and fusion, with an emphasis on assessing any deterioration in outcomes over time.
Materials and Methods

Subjects and Study Design
T he study design has been reported elsewhere 5 . Briefly, eligible patients were at least twenty-one years old and had radiculopathy or myelopathy from single-level cervical disc disease secondary to disc herniation or focal osteophytes that had not responded to at least six weeks of nonoperative management. All investigational sites had institutional review board approval, and all patients provided voluntary informed consent to participate in the study. Patients were randomly assigned in a 1:1 ratio to one of two treatment groups: arthroplasty with use of an artificial disc, the Bryan Cervical Disc (Medtronic Spinal and Biologics) (Fig. 1 ), or fusion with anterior cervical plate stabilization and bone allograft. The surgical procedures were performed at thirty investigational sites by sixty-five investigators and coinvestigator surgeons. The procedure in the fusion group was standardized by using both a commercially available allograft (Cornerstone; Medtronic Spinal and Biologics) and a single anterior cervical plating system (Atlantis; Medtronic Spinal and Biologics). The patients in the arthroplasty group were treated with a two-week postoperative course of a nonsteroidal anti-inflammatory drug of their surgeon's choice. Recommendations for immobilization with either soft or hard cervical collars, or the imposition of activity restrictions, were left to the discretion of the surgeon for both patient cohorts.
The initial study end point was twenty-four months for the investigational device exemption clinical trial. However, as a condition for approval of this device, the U.S. Food and Drug Administration (FDA) required the manufacturer to extend its follow-up of enrolled subjects to ten years after surgery. This required each investigative center to reapply for institutional review board approval. Furthermore, renewed informed consent was acquired from willing study participants. Patients were evaluated, according to protocol-defined intervals, preoperatively, at the time of surgery and discharge, at six weeks, and at three, six, twelve, twentyfour, and forty-eight months postoperatively.
Outcomes Assessment
Pain and function were assessed with use of the Neck Disability Index (NDI) 6, 7 , the Short Form-36 (SF-36) 8 , and numeric rating scales for neck and arm pain. Standardized neurological examinations, including motor and sensory function and reflexes, were recorded by the investigator or nursing staff. Neurological success was defined as maintenance or improvement of all three neurological parameters (motor and sensory function and reflexes). Radiographs were made preoperatively, prior to hospital discharge, and at three, six, twelve, twenty-four, and forty-eight months after surgery. All images were stored centrally and read by independent radiologists. All adverse events were recorded prospectively, categorized, evaluated for causality, and graded for severity with use of World Health Organization (WHO) criteria 9 . All were then reviewed for accuracy of categorization, causality, and severity by an independent physician.
The primary end point for the study was a composite measure termed overall success, consisting of the primary effectiveness and safety measures. To have the outcome be considered an overall success, patients had to achieve all of the following: an improvement of ‡15 points in the NDI, neurological improvement, no serious (WHO grade-3 or 4) adverse events related to the implant or surgical implantation procedure, and no subsequent surgery or intervention that would be classified as a treatment failure.
Patients were evaluated for flexion-extension motion of the cervical spine with use of the Cobb measurement technique on dynamic lateral radiographs of the cervical spine 10 . For each measurement, the means from two reviewers were calculated and used for analysis.
Statistical Methods
The primary analysis dataset consisted of all patients who received one of the study treatments. Statistical comparisons were primarily based on the observed and recorded follow-up data. A small number of patients required an additional surgical procedure (removal, revision, or supplemental fixation); their outcomes were recorded as a treatment failure for overall success-the primary study end point. For other outcome variables, the last-observation-carriedforward technique was used for all future evaluation periods.
To compare patients' demographic and preoperative measures, an analysis of variance was used for continuous variables and the Fisher exact test was used for categorical variables. For comparisons of postoperative mean The Bryan disc is composed of a polyurethane nucleus in a saline solution bath sandwiched between two titanium end plates wrapped by a polyurethane sleeve.
scores or mean score improvements measured in continuous scales, such as NDI scores, analysis of covariance was used with the preoperative score as the covariate. To assess the significance of improvement in the outcome measures within each treatment group, a paired t test was used. For comparison of success or event rates, the Fisher exact test was used to assess the superiority hypothesis.
One-sided p values were reported for most clinical outcomes as defined in the protocol except for surgery and return-to-work data, adverse events, and additional surgical procedures, which were two-sided. A p value of £0.05 was considered as significant.
Preoperative Comparison
From May 2002 to October 2004, a total of 463 enrolled subjects were randomly assigned to the study groups, with 242 assigned to the arthroplasty group and 221 to the fusion group. Two-year follow-up was achieved for 230 patients in the arthroplasty group and 194 in the fusion group whose data had been previously reported 5 . The current study involves the 181 arthroplasty and 138 fusion patients at the four-year follow-up (Fig. 2 ). Preoperative characteristics of the patients and preoperative clinical measures were similar in the two groups (see Appendix). There were no differences in demographics, disease severity (NDI and pain scores), and treated levels between the two groups preoperatively. Similarly, there were no differences between the treatment groups with regard to these preoperative variables for patients with complete forty-eight-month follow-up.
Source of Funding
Medtronic funded the investigational device exemption clinical trial and its continuation as a postapproval study. The clinical trials identification number is NCT00437190.
Results
Overall Success
A t every time point postoperatively, the primary outcome measure of overall success was significantly superior for the arthroplasty group compared with the fusion cohort (Fig.  3) . At the four-year postoperative mark, overall success was achieved in 85.1% of the patients in the arthroplasty group and Flow diagram of patient randomization and follow-up.
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72.5% in the fusion group (Table I ) (p = 0.004). No deterioration over time was observed in either group.
Neck Disability Index
At every time point postoperatively, the two groups were significantly improved from their preoperative state and the arthroplasty group was significantly superior compared with the arthrodesis cohort (Fig. 4) . At the four-year postoperative mark, the mean NDI was 13.2 (95% confidence interval [CI]: 10.9 to 15.6) in the arthroplasty group and 19.8 (95% CI: 16.5 to 23.2) in the arthrodesis group (p < 0.001). Improvement was seen rapidly within six weeks after surgery, and a plateau was reached by three months in the arthroplasty group and by six months in the fusion group.
Neck Disability Index Success
At every time point postoperatively, the percentage of the arthroplasty group who had a reduction of ‡15 points in NDI scores, a criterion for overall success, was significantly higher than that of the fusion group (Fig. 5) . At the four-year postoperative mark, NDI success was achieved in 90.6% of the arthroplasty group and in 79.0% of the fusion group (p = 0.003).
Neurological Success
Neurological success rates at forty-eight months were similar to those observed at twenty-four months. The mean rates were 92.8% and 89.9% in the arthroplasty group and fusion group, respectively, and were not significantly different between the groups (Table I and Appendix) . Overall clinical success. The difference between the arthroplasty and fusion groups was significant at all time points.
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Arm Pain
The score for arm pain improved rapidly from a mean preoperative score of 71.2 for both groups to 16.6 (95% CI: 13.1 to 20.2) and 22.4 (95% CI: 17.7 to 27.1) at forty-eight months of follow-up for the arthroplasty and fusion groups, respectively (p = 0.028). Small but significant differences in improvement of the arm pain score were detected between the groups at twelve and forty-eight months, favoring the arthroplasty group over the fusion group (see Appendix).
Neck Pain
The mean preoperative score for neck pain was 75.4 and 74.8 for the arthroplasty and fusion groups, respectively, while at forty-eight months, the mean neck pain score decreased to 20.7 Neck Disability Index (NDI) score. Significant improvement occurred from baseline in both groups.
Furthermore, the difference in improvement between groups was significant at all time points.
The results were durable for both groups and did not show significant change over time after three months. 1688
(95% CI: 17.0 to 24.4) and 30.6 (95% CI: 25.5 to 35.8), respectively. Significant improvement in the neck pain score occurred by six weeks and was maintained at forty-eight months for both groups. The improvement was significantly greater in the arthroplasty group at all time points (Fig. 6 ).
SF-36 Summary Scores
Health-related quality of life was assessed by the SF-36 physical component and mental component summary scores. At fortyeight months, the mean postoperative SF-36 physical component and mental component scores had significantly improved The scores for neck pain on the visual analog scale. Improvement in the neck pain score for the arthroplasty group was significantly better than that in the fusion group at all time points. SF-36 physical component summary (PCS) score. The physical functional outcome was significantly better in the arthroplasty group compared with the fusion group at forty-eight months postoperatively.
for both treatment groups compared with preoperative levels. Furthermore, at forty-eight months, the mean SF-36 physical component score improvement was significantly better in the arthroplasty group compared with the fusion group (p = 0.007). The mean preoperative SF-36 physical component scores were 32.6 and 31.8 for the arthroplasty and fusion groups, respectively, increasing to 48.4 (95% CI: 46.8 to 49.9) and 44.9 (95% CI: 43.0 to 46.9) at forty-eight months (Fig. 7) . The mean mental component score at the preoperative evaluation was 42.3 and 44.6 for the arthroplasty and fusion groups, respectively, increasing to 52.6 (95% CI: 51.1 to 54.0) and 51.9 (95% CI: 50.3 to 53.6) at forty-eight months.
The key pain and functional outcome scores at the preoperative evaluation and at two years and four years of followup are presented in Table II .
Return to Work
Preoperatively, 64.5% and 65% of the patients in the arthroplasty and fusion groups, respectively, were working. At six weeks after surgery, there were significantly more patients (49.2%) who had returned to work in the arthroplasty group than in the fusion group (39.4%). At forty-eight months, 74.7% and 67.9%, respectively, of the patients were working; the difference was not significant (see Appendix).
Range of Motion
The mean cervical spine motion in flexion-extension for the single-level arthroplasty group increased from 6.5°(95% CI: 6.0°to 6.9°) at baseline to 8.08°at twenty-four months and 8.5°(95% CI: 7.7°to 9.2°) at forty-eight months. This increase from baseline was significant at all time points after three months (p < 0.05). The fusion group showed a mean decrease of motion from 8.4°to 1.1°at forty-eight months.
Adverse Events
Adverse events that occurred up to two years postoperatively have been previously reported 5 . For this study, we report only the more severe WHO 9 grade-3 and 4 complications that occurred after twenty-four months and up to the forty-eightmonth evaluation window. Forty-four patients in the arthroplasty Other cervical levels
*Two-sided p values were from Fisher exact test. †Some secondary procedures were involved with both index and adjacent levels, and they were counted for index level only in this table.
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group had sixty-three adverse events classified as WHO grade 3 or 4 compared with thirty-six patients in the fusion group who had sixty-four adverse events; the difference was not significant. Most of these events were medical problems unrelated to the index surgery or the cervical spine. Severe episodes of neck and arm pain occurred in three and five patients in the arthroplasty and fusion groups, respectively. New neurologic deficits occurred in two patients in the fusion group.
Secondary Procedures
Cumulatively, up to the forty-eight-month evaluation window, nine patients (3.7%) in the arthroplasty group and ten (4.5%) in the fusion group had secondary surgical procedures involving the index cervical spine level (Table III) ; the difference is not significant. Secondary surgical procedures occurred in three patients in the arthroplasty group and two in the fusion group after twenty-four months and up to forty-eight months. Among them, one patient in each group had the device removed. The investigational device was explanted, and an arthrodesis performed, because of continued neck and shoulder pain. At adjacent levels, cumulatively up to the fortyeight-month evaluation window, the rates of secondary surgical procedures were the same (4.1%) in both treatment groups (Table  III) .
Discussion
A multicenter, prospective, randomized study with two-year follow-up of artificial cervical disc replacement compared with anterior cervical fusion for one-level degenerative disc disease showed significant differences between the groups 5 . For one-level cervical artificial disc replacement, improved functional outcomes were demonstrated for overall success, NDI, NDI success, and visual analog scale scores for neck pain. At four years postoperatively, we continued to see favorable outcomes for the artificial disc cohort, without any degradation of outcome measures between two and four years postoperatively. At forty-eight months, the arthroplasty cohort continued to show sustained, significantly superior outcomes, with a significantly higher rate of overall success and significantly greater improvements in NDI, neck pain scores, and SF-36 physical component scores. The improvement in arm pain scores was also significantly greater in the arthroplasty cohort at fortyeight months.
New technology such as disc arthroplasty requires longterm follow-up to assess durability, the biologic effects of wear, and the response of the prosthesis to its environment. Failure of other joint arthroplasty prostheses does not typically occur until at least five to ten years postoperatively. Spinal arthroplasties similarly need to have serial assessments to determine whether complications such as wear-related failures, device fatigue, or spinal instability have developed. The authors support the FDA requirement that the study sponsor be responsible for attempting to follow all willing study participants for up to eight years after the surgery.
Four years postoperatively, the arthroplasty prosthesis has proven quite durable, with few failures or explants and no change in neck motion over time. Few adverse events occurred in either group after twenty-four months. Spine or devicerelated events were primarily related to pain at the treated or adjacent disc levels. In the arthroplasty group, explantation occurred in one patient for continued pain. No arthroplasty device required removal for wear or wear-related failure. No new serious adverse event related to the device occurred. In the fusion group, reoperations occurred because of persistent pseudarthrosis and adjacent segment disc disease. Overall, the rates of reoperation are low in both the arthroplasty and fusion groups, with no significant difference detected.
The limitations of this four-year study mainly revolve around the relatively low rate of follow-up compared with the two-year study. At twenty-four months, 230 patients (95%) in the arthroplasty group were evaluated, while at forty-eight months, 181 (75%) were available. For the fusion group, 38% of the 221 enrolled patients failed to return for follow-up at forty-eight months. The lower rate may lead to attrition bias and affect the validity of our results. The actual results may therefore be at variance with the ones reported in this study.
This lower follow-up rate was caused by the original study design, which was set for only two years. A longer followup period was requested by FDA regulators; however, this required institutional review board approval at each treatment center and renewed consent and authorization from each patient. As a result, not all centers participated in the longer follow-up study and not all patients consented to the longer follow-up period. Additionally, even for the patients and sites who wished to participate in the longer follow-up period, logistical issues prevented many patients from completing the forty-eight-month follow-up. The follow-up rate was lower at forty-eight months because of the timing of FDA and institutional review board approvals. The forty-eight-month followup period was added to the protocol by an amendment. This required time to obtain FDA approval. After FDA approval, the sites had to submit to their institutional review boards, which often took much more time. During this time, the follow-up period for thirty-one patients had ended, and by the time approvals were obtained, the patients were in their sixtieth month of follow-up. Although it is a minor change in the wording of the initial study protocol, the stipulated period of allowed follow-up and the duration of informed consent should either be open-ended or at least be indicated as eight to ten years. This would preempt the barriers with regard to institutional review boards and informed consent faced in this longer-term followup effort.
No deterioration of outcomes after anterior cervical plate stabilization and bone allograft was noticed at four years postoperatively. Clinical improvement, however, continued to be significantly better in the arthroplasty group compared with the fusion group in the primary outcome variables at the time of the four-year follow-up. An additional advantage to the arthroplasty group is that these benefits were obtained while preserving cervical spine motion. As for any motion-sparing device, however, longer-term follow-up is necessary for assessment of potential problems related to bearing surface wear.
